Outcomes26

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 20 of 26

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Time to Discontinuation Due to Adverse Event (AE)	Baseline through 24 weeks	All randomized participants.	days	MEAN
SECONDARY	Number of Participants With Shift From Baseline to Maximum Post-Baseline Grading in Electroencephalograms (EEGs)	Baseline through 52 weeks	All randomized participants with both baseline and at least one post-baseline value.	participants	NUMBER
SECONDARY	Number of Participants With Potentially Clinically Significant Changes in QT Intervals Electrocardiograms (ECGs)	Baseline through 24 weeks	All randomized participants with normal baseline measurement and at least one post-baseline measurement.	participants	NUMBER
SECONDARY	Number of Participants With Treatment-Emergent Change in Neurological Examination	Baseline through 52 weeks	All randomized participants.	participants	NUMBER
SECONDARY	Change From Baseline in Blood Pressure (BP) at 52 Weeks Endpoint	Baseline, 52 weeks	All randomized participants with both baseline and at least one non-missing post-baseline value.	millimeters of mercury (mmHg)	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Weight at 52 Weeks Endpoint	Baseline, 52 weeks	All randomized participants with both baseline and at least one non-missing post-baseline value.	kilogram (kg)	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Pulse Rate at 52 Weeks Endpoint	Baseline, 52 weeks	All randomized participants with both baseline and at least one non-missing post-baseline value.	beats per minute (bpm)	LEAST_SQUARES_MEAN
SECONDARY	Number of Participants With Potentially Clinical Significant Change in Fasting Glucose Level	Baseline through 52 weeks	All randomized participants with a normal baseline and at least one post-baseline result.	participants	NUMBER
SECONDARY	Number of Participants With Potentially Clinical Significant Change in Lipids Level	Baseline through 52 weeks	All randomized participants with a normal baseline and at least one post-baseline value.	participants	NUMBER
SECONDARY	Number of Participants With Suicidal Behaviors and Ideations Baseline Through 52 Weeks	Baseline through 52 weeks	All randomized participants with at least one post-baseline C-SSRS value.	participants	NUMBER
SECONDARY	Change From Baseline in Positive and Negative Syndrome Scale (PANSS) at 52 Weeks Endpoint	Baseline, 52 weeks	All randomized participants with both baseline and at least one non-missing post-baseline value.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Clinical Global Impression Severity Scale (CGI-S) at 52 Weeks Endpoint	Baseline, 52 weeks	All randomized participants with both baseline and at least one non-missing post-baseline value.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in 16-Item Negative Symptoms Assessment (NSA-16) Total Score at 52 Weeks Endpoint	Baseline, 52 weeks	All randomized participants with both baseline and at least one non-missing post-baseline value.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB): Overall Composite T-Score at 52 Weeks Endpoint	Baseline, 52 weeks	All randomized participants with both baseline and at least one non-missing post-baseline value.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 52 Weeks Endpoint	Baseline, 52 weeks	All randomized participants with both baseline and at least one non-missing post-baseline value.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in University of California-San Diego (UCSD) Performance-Based Skills Assessment-B (UPSA-B) Total Score at 52 Weeks Endpoint	Baseline, 52 weeks	All randomized participants with both baseline and at least one non-missing post-baseline value.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Percentage of Participants With Response (Rate of Response) at 6 and 24 Weeks Endpoints	6 and 24 weeks	All randomized participants with both baseline and at least one post-baseline PANSS values.	percentage of participants	NUMBER
SECONDARY	Percentage of Participants With Remission (Rate of Remission) at Week 24 Endpoint	24 weeks	All randomized participants with both baseline and at least one post-baseline PANSS values.	percentage of participants	NUMBER
SECONDARY	Percentage of Participants With Relapse (Rate of Relapse)	Baseline through 52 weeks	All randomized participants with non-missing relapse flag.	percentage of participants	NUMBER
SECONDARY	Change From Baseline in Subjective Well-Being Under Neuroleptic Treatment-Short Form (SWN-S) Total Score at 52 Weeks Endpoint	Baseline, 52 weeks	All randomized participants with both baseline and at least one non-missing post-baseline value.	units on a scale	LEAST_SQUARES_MEAN

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00845026/outcomes

API reference For AI assistants

Outcomes26

Sources 3

Read this list from software.